Esophageal Adenocarcinoma Methods and Protocols

(sharon) #1

210


https://doi.org/10.1158/1055-9965.
epi-07-2734


  1. Miller CT, Aggarwal S, Lin TK, Dagenais SL,
    Contreras JI, Orringer MB, Glover TW, Beer
    DG, Lin L (2003) Amplification and overex-
    pression of the dual-specificity tyrosine-(Y)-
    phosphorylation regulated kinase 2 (DYRK2)
    gene in esophageal and lung adenocarcinomas.
    Cancer Res 63:4136–4143

  2. Hasina R, Mollberg N, Kawada I, Mutreja K,
    Kanade G, Yala S, Surati M, Liu R, Li X, Zhou
    Y, Ferguson BD, Nallasura V, Cohen KS,
    Hyjek E, Mueller J, Kanteti R, El Hashani E,
    Kane D, Shimada Y, Lingen MW, Husain AN,
    Posner MC, Waxman I, Villaflor VM, Ferguson
    MK, Varticovski L, Vokes EE, Gill P, Salgia R
    (2013) Critical role for the receptor tyrosine
    kinase EPHB4 in esophageal cancers. Cancer
    Res 73:184–194. https://doi.org/10.1158/
    0008-5472.can-12-0915

  3. Hjortland GO, Meza-Zepeda LA, Beiske K,
    Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole
    KH, Myklebost O, Fodstad O, Smeland S,
    Hovig E (2011) Genome wide single cell anal-
    ysis of chemotherapy resistant metastatic cells
    in a case of gastroesophageal adenocarcinoma.
    BMC Cancer 11:455. https://doi.
    org/10.1186/1471-2407-11-455

  4. Tokunaga R, Imamura Y, Nakamura K,
    Ishimoto T, Nakagawa S, Miyake K, Nakaji Y,
    Tsuda Y, Iwatsuki M, Baba Y, Sakamoto Y,
    Miyamoto Y, Saeki H, Yoshida N, Oki E,
    Watanabe M, Oda Y, Bass AJ, Maehara Y, Baba
    H (2016) Fibroblast growth factor receptor 2
    expression, but not its genetic amplification, is
    associated with tumor growth and worse sur-
    vival in esophagogastric junction adenocarci-
    noma. Oncotarget 7:19748–19761. https://
    doi.org/10.18632/oncotarget.7782

  5. Walch A, Specht K, Braselmann H, Stein H,
    Siewert JR, Hopt U, Hofler H, Werner M
    (2004) Coamplification and coexpression of
    GRB7 and ERBB2 is found in high grade
    intraepithelial neoplasia and in invasive Barrett's
    carcinoma. Int J Cancer 112:747–753.
    https://doi.org/10.1002/ijc.20411

  6. Kumarasinghe MP, de Boer WB, Khor TS, Ooi
    EM, Jene N, Jayasinghe S, Fox SB (2014)
    HER2 status in gastric/gastro-esophageal
    junctional cancers: should determination of
    gene amplification by SISH use HER2 copy
    number or HER2: CEP17 ratio? Pathology
    46:184–187. https://doi.org/10.1097/
    pat.0000000000000075

  7. Lange T, Nentwich MF, Luth M, Yekebas E,
    Schumacher U (2011) Trastuzumab has anti-
    metastatic and anti-angiogenic activity in a
    spontaneous metastasis xenograft model of


esophageal adenocarcinoma. Cancer Lett
308(1):54–61. https://doi.org/10.1016/j.
canlet.2011.04.013


  1. Safran H, Dipetrillo T, Akerman P, Ng T,
    Evans D, Steinhoff M, Benton D, Purviance J,
    Goldstein L, Tantravahi U, Kennedy T (2007)
    Phase I/II study of trastuzumab, paclitaxel,
    cisplatin and radiation for locally advanced,
    HER2 overexpressing, esophageal adenocarci-
    noma. Int J Radiat Oncol Biol Phys 67:405–
    409. https://doi.org/10.1016/j.
    ijrobp.2006.08.076

  2. Michalk M, Meinrath J, Kunstlinger H,
    Koitzsch U, Drebber U, Merkelbach-Bruse S,
    Bollschweiler E, Kloth M, Hartmann W,
    Holscher A, Quaas A, Grimminger PP,
    Odenthal M (2016) MDM2 gene amplification
    in esophageal carcinoma. Oncol Rep 35:2223–
    2227. https://doi.org/10.3892/
    or.2016.4578

  3. Pal J, Bertheau R, Buon L, Qazi A, Batchu RB,
    Bandyopadhyay S, Ali-Fehmi R, Beer DG,
    Weaver DW, Shmookler Reis RJ, Goyal RK,
    Huang Q, Munshi NC, Shammas MA (2011)
    Genomic evolution in Barrett’s adenocarci-
    noma cells: critical roles of elevated hsRAD51,
    homologous recombination and Alu sequences
    in the genome. Oncogene 30:3585–3598.
    https://doi.org/10.1038/onc.2011.83

  4. Lockwood WW, Thu KL, Lin L, Pikor LA,
    Chari R, Lam WL, Beer DG (2012) Integrative
    genomics identified RFC3 as an amplified can-
    didate oncogene in esophageal adenocarci-
    noma. Clin Cancer Res 18:1936–1946.
    https://doi.org/10.1158/1078-0432.
    ccr-11-1431

  5. Akagi T, Ito T, Kato M, Jin Z, Cheng Y, Kan T,
    Yamamoto G, Olaru A, Kawamata N, Boult J,
    Soukiasian HJ, Miller CW, Ogawa S, Meltzer
    SJ, Koeffler HP (2009) Chromosomal abnor-
    malities and novel disease-related regions in
    progression from Barrett’s esophagus to esoph-
    ageal adenocarcinoma. Int J Cancer 125:2349–
    2359. https://doi.org/10.1002/ijc.24620

  6. Pang C, LaLonde A, Godfrey TE, Que J, Sun
    J, Wu TT, Zhou Z (2017) Bile salt receptor
    TGR5 is highly expressed in esophageal adeno-
    carcinoma and precancerous lesions with sig-
    nificantly worse overall survival and gender
    differences. Clin Exp Gastroenterol 10:29–37.
    https://doi.org/10.2147/ceg.s117842

  7. Leicht DT, Kausar T, Wang Z, Ferrer-Torres
    D, Wang TD, Thomas DG, Lin J, Chang AC,
    Lin L, Beer DG (2014) TGM2: a cell surface
    marker in esophageal adenocarcinomas.
    J Thorac Oncol 9:872–881. https://doi.
    org/10.1097/jto.0000000000000229


Katherine T. W. Lee et al.
Free download pdf